Impact of STAT3 inhibition on survival of osteosarcoma cell lines

Anticancer Research

Volumn 34, Issue 11, 2014, Pages 6537-6545

  Wang, Xiaochun ^a   Goldstein, David ^a   Crowe, Philip J ^a   Yang, Jia Lin ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Osteosarcoma; S3I 201; STAT3

Indexed keywords

4 [[(4 METHYLPHENYL)SULFONYLOXY]ACETAMIDO]SALICYLIC ACID; CASPASE 3; CRYSTAL VIOLET; CYCLIN D1; STAT3 PROTEIN; SURVIVIN; AMINOSALICYLIC ACID DERIVATIVE; BENZENESULFONIC ACID DERIVATIVE; STAT3 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CLONOGENIC ASSAY; COLONY FORMATION; COLORIMETRY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL LINE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; METABOLISM; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

AMINOSALICYLIC ACIDS; APOPTOSIS; BENZENESULFONATES; BLOTTING, WESTERN; BONE NEOPLASMS; CELL PROLIFERATION; HUMANS; OSTEOSARCOMA; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 84916217259     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004. Cancer 115: 1531-1543, 2009.
2. Yamamoto N and Tsuchiya H: Chemotherapy for osteosarcoma - Where does it come from? What is it? Where is it going? Expert Opin Pharmacother 14: 2183-2193, 2013.
3. Nathan SS and Healey JH: Demographic determinants of survival in osteosarcoma. Ann Acad Med Singapore 41: 390-399, 2012.
4. Heare T, Hensley MA and Dell'Orfano S: Bone tumors: osteosarcoma and Ewing's sarcoma. Curr Opin Pediatr 21: 365-372, 2009.
5. Whelan J, McTiernan A, Cooper N, Wong YK, Francis M, Vernon S and Strauss SJ: Incidence and survival of malignant bone sarcomas in England 1979-2007. Int J Cancer 131: E508-E517, 2012.
6. Ando K, Heymann MF, Stresing V, Mori K, Redini F and Heymann D: Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel) 5: 591-616, 2013.
7. Posthumadeboer J, Witlox MA, Kaspers GJ and van Royen BJ: Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis 28: 493-503, 2011.
8. Chou AJ, Geller DS and Gorlick R: Therapy for Osteosarcoma: Where Do We Go From Here? Paediatr Drugs 10: 315-327, 2008.
9. Wang X, Crowe PJ, Goldstein D and Yang J-L: STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (Review). Int J Oncol 41: 1181-1191, 2012.
10. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S and Sung B: Signal Transducer and Activator of Transcription-3, Inflammation, and Cancer. Ann NY Acad Sci 1171: 59-76, 2009.
11. Sahu RP and Srivastava SK: The Role of STAT-3 in the Induction of Apoptosis in Pancreatic Cancer Cells by Benzyl Isothiocyanate. JNCI Journal of the National Cancer Institute 101: 176-193, 2009.
12. Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao D, Kalvakolanu DV, Kopecko DJ, Zhao X and Xu D-Q: Down-Regulation of Signal Transducer and Activator of Transcription 3 Expression Using Vector-Based Small Interfering RNAs Suppresses Growth of Human Prostate Tumor In vivo. Clin Cancer Res 11: 6333-6341, 2005.
13. Bhutani M, Pathak AK, Nair AS, Kunnumakkara AB, Guha S, Sethi G and Aggarwal BB: Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation. Clin Cancer Res 13: 3024-3032, 2007.
14. Kim SM, Kwon O-J, Hong YK, Kim JH, Solca F, Ha S-J, Soo RA, Christensen JG, Lee JH and Cho BC: Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther 11: 2254-2264, 2012.
15. Wang X, Goldstein D, Crowe P, J and Yang J-L: S3I-201, a novel STAT3 inhibitor, inhibits growth of human soft tissue sarcoma cell lines. world J Cancer Res 1: 61-68, 2013.
16. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip MLR, Jove R, McLaughlin MM, Lawrence NJ, Sebti SM and Turkson J: Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proceedings of the National Academy of Sciences 104: 7391-7396, 2007.
17. Chen W, Shen X, Xia X, Xu G, Ma T, Bai X and Liang T: NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma. Liver International 32: 70-77, 2012.
18. Hu Q-D, Chen W, Yan T-L, Ma T, Chen C-L, Liang C, Zhang Q, Xia X-F, Liu H, Zhi X, Zheng X-X, Bai X-L, Yu X-Z and Liang T-B: NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells. Cancer Lett 325: 207-213, 2012.
19. Chen C-L, Loy A, Cen L, Chan C, Hsieh F-C, Cheng G, Wu B, Qualman SJ, Kunisada K, Yamauchi-Takihara K and Lin J: Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer 7: 111, 2007.
20. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A and Jove R: Constitutive activation of STAT3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20: 2499-2513, 2001.
21. Ni Z, Lou W, Leman ES and Gao AC: Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res 60: 1225-1228, 2000.
22. Sanchez A, Nagy P and Thorgeirsson SS: STAT-3 activity in chemically-induced hepatocellular carcinoma. Eur J Cancer 39: 2093-2098, 2003.
23. David D, Rajappan LM, Balachandran K, Thulaseedharan JV, Nair AS and Pillai RM: Prognostic significance of STAT3 and phosphorylated STAT3 in human soft tissue tumors - a clinicopathological analysis. J Exp Clin Cancer Res 30: 56, 2011.
24. Wang Y-C, Zheng L-H, Ma B-A, Zhou Y, Zhang M-H, Zhang D-Z and Fan Q-Y: Clinical value of signal transducers and activators of transcription 3 (STAT3) gene expression in human osteosarcoma. Acta Histochem 113: 402-408, 2011.
25. Ryu K, Choy E, Yang C, Susa M, Hornicek FJ, Mankin H and Duan Z: Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis. J Orthop Res 28: 971-978, 2010.
26. Sporeno E, Savino R, Ciapponi L, Paoinessa G, Cabibbo A, Lahm A, Pulkki K, Sun R-X, Toniatti C, Klein B and Ciliberto G: Human Interleukin-6 Receptor Super-Antagonists With High Potency and Wide Spectrum on Multiple Myeloma Cells. Blood 87: 4510-4519, 1996.
27. Demartis A, Bernassola F, Savino R, Melino G and Ciliberto G: Interleukin 6 receptor superantagonists are potent inducers of Human Multiple. Cancer Res 56: 4213-4218, 1996.
28. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS and Jove R: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 Myeloma Cells. Immunity 10: 105-115, 1999.
29. Johnson FM, Saigal B, Talpaz M and Donato NJ: Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11: 6924-6932, 2005.
30. Niu G, Shain KH, Huang M, Ravi R, Bedi A, Dalton WS, Jove R and Yu H: Overexpression of a dominant-negative signal Transducer and Activator of Trnascription 3 Varian in Tumor Cells Leads to Production of Soluble Factors That Induce Apoptosis and Cell Cycle Arrest. Cancer Res 61: 3276-3280, 2001.
31. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R and Yu H: Constitutive STAT3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008, 2002.
32. Song H, Wang R, Wang S and Lin J: A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 102: 4700-4705, 2005.
33. Schust J, Sperl B, Hollis A, Mayer TU and Berg T: Stattic: A Small-Molecule Inhibitor of STAT3 Activation and Dimerization. Chem Biol 13: 1235-1242, 2006.
34. Lin L, Amin R, Gallicano GI, Glasgow E, Jogunoori W, Jessup JM, Zasloff M, Marshall JL, Shetty K, Johnson L, Mishra L and He AR: The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling. Oncogene 28: 961-972, 2009.
35. Barton BE, Karras JG, Murphy tF, Barton A and Huang HF-S: Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Molecular Cancer Therapeutic 3: 11-20, 2004.
36. Mora LB, Buettner R, Seigne J, Jose D, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S and Karras J: Constitutive activation of Atat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62: 6659-6666, 2002.
37. Chen CL, Hsieh FC, Lieblein JC, Brown J, Chan C, Wallace JA, Cheng G, Hall BM and Lin J: Stat3 activation in human endometrial and cervical cancers. Br J Cancer 96: 591-599, 2007.
38. Fan TJ, Han LH, Cong RS and Liang J: Caspase family proteases and apoptosis. Acta Biochim Biophys Sin 37: 719-727, 2005.
39. Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, Tomita K, Komiyama S and Weinstein B: Constitutive activation of signal transducers and activators of transcription 3 correlates with Cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 62: 3351-3355, 2002.
40. Lin L, Hutzen B, Li P-K, Ball S, Zuo M, DeAngelis S, Foust E, Sobo M, Friedman L, Bhasin D, Cen L, Li C and Lin J: A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activites and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia 12: 39-50, 2010.
41. Ball S, Li C, Li P-K and Lin J: The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells. PLoS One 6: e18820, 2011.
42. Matsuno K, Masuda Y, Uehara Y, Sato H, Muroya A, Takahashi O, Yokotagawa T, Furuya T, Okawara T, Otsuka M, Ogo N, Ashizawa T, Oshita C, Tai S, Ishii H, Akiyama Y and Asai A: Identification of a new series of STAT3 inhibitors by virtual screening. ACS Med Chem Lett 1: 371-375, 2010.
43. Ashizawa T, Miyata H, Ishii H, Oshita C, Matsuno K, Masuda Y, Furuya T, Okawara T, Otsuka M, Ogo N, Asai A and Akiyama Y: Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation. Int J Oncol 382011.
44. Tu B, Du L, Fan Q-M, Tang Z and Tang T-T: STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. Cancer Lett 325: 80-88, 2012.
45. Ryu K, Susa M, Choy E, Yang C, Hornicek FJ, Mankin HJ and Duan Z: Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway. BMC Cancer 10: 187, 2010.